Abacavir hypersensitivity reaction: An update

Annals of Pharmacotherapy

Volumn 42, Issue 3, 2008, Pages 387-396

  Hughes, Christine A ^a,b   Foisy, Michelle M ^c   Dewhurst, Norman ^d   Higgins, Niamh ^e   Robinson, Linda ^f   Kelly, Deborah V ^g,h   Lechelt, Kelly E ⁱ  

^a UNIVERSITY OF ALBERTA   (Canada)

^b HIV   (Canada)

^c HIV Social   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^f WINDSOR REGIONAL HOSPITAL   (Canada)

^g MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^h Eastern Health Canada   (Canada)

ⁱ CROSS CANCER INSTITUTE   (Canada)

Author keywords

Abacavir; Drug hypersensitivity; HIV; Hla b*5701

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ANALGESIC AGENT; ANTIEMETIC AGENT; ANTIPRURITIC AGENT; ANTIPYRETIC AGENT; CIPROFIBRATE; CORTICOSTEROID; HLA B ANTIGEN;

ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ADULT RESPIRATORY DISTRESS SYNDROME; AGRANULOCYTOSIS; AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ARTHRALGIA; CERVICAL LYMPHADENOPATHY; CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; COUGHING; CREATINE BLOOD LEVEL; CREATINE KINASE BLOOD LEVEL; DIAGNOSTIC PROCEDURE; DIARRHEA; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; ETHNICITY; FACE EDEMA; FEVER; GENERALIZED EDEMA; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETICS; HEADACHE; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDRATION; HYPERSENSITIVITY REACTION; HYPOTENSION; IMMUNOGENETICS; INTERPERSONAL COMMUNICATION; LEUKOPENIA; LYMPHOCYTOPENIA; MACULOPAPULAR RASH; MALAISE; MEDICAL ASSESSMENT; MEDLINE; MYALGIA; NAUSEA; PATCH TEST; PATIENT EDUCATION; PHARMACOGENETICS; PHARMACOGENOMICS; PHARYNGITIS; PRIORITY JOURNAL; PRURITUS; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; STEVENS JOHNSON SYNDROME; TACHYCARDIA; THROMBOCYTOPENIA; VOMITING;

ANTI-HIV AGENTS; DIDEOXYNUCLEOSIDES; DRUG HYPERSENSITIVITY; HIV INFECTIONS; HLA-B ANTIGENS; HUMANS;

EID: 41149096014     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K522     Document Type: Review

References (56)

1. Product monograph. Ziagen (abacavir sulfate) GlaxoSmithKline Inc., October 2006. http://us.gsk.com/products/assets/us_ziagen_tablets.pdf (accessed 2007 Sept 16).
2. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. January 29, 2008. www.aidsinfo.nih.gov/guidelines (accessed 2008 Feb 7).
3. Lee H, Hanes J, Johnson KA. Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. Biochemistry 2003;42:14711-9. DOI 10.1021/bi035596s
4. Moyle G. Mechanisms of HIV and nucleoside reverse transcriptase inhibitor injury to mitochondria. Antivir Ther 2005;10(suppl 2):M47-52.
5. Dando TM, Scott LJ. Abacavir plus lamivudine: a review of their combined use in the management of HIV infection. Drugs 2005;65:285-302.
6. Anderson AM, Bartlett JA. Fixed dose combination abacavir/lamivudine in the treatment of HIV-1 infection. Expert Rev Anti Infect Ther 2005;3:871-83. DOI 10.1586/14787210.3.6.871
7. Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 2001;23:1603-14. DOI 10.1016/S0149-2918(01)80132-6
8. Clay PG. The abacavir hypersensitivity reaction: a review. Clin Ther 2002;24:1502-14. DOI 10.1016/S0149-2918(02)80057-1
9. Hewitt RG. Abacavir hypersensitivity reaction. Clin Infect Dis 2002;34:1137-42. DOI 10.1086/339751
10. Temesgen Z, Beri G. HIV and drug allergy. Immunol Allergy Clin North Am 2004;24:521-31. DOI 10.1016/j.iac.2004.03.006
11. de la Rosa R, Harris M, Uyeda L, Goodison K, Keown P, Montaner JS. Life-threatening reaction after first ever dose of abacavir in an HIV-1 infected patient. AIDS 2004;18:578-9. DOI 10.1097/00002030-200402200-00032
12. Fontaine C, Guiard-Schmid JB, Slama L, et al. Severe rhabdomyolysis during a hypersensitivity reaction to abacavir in a patient treated with ciprofibrate. AIDS 2005;19:1927-8. DOI 10.1097/01.aids.0000189861.44311.ed
13. Dargere S, Verdon R, Bouhier K, Bazin C. Disseminated intravascular coagulation as a manifestation of abacavir hypersensitivity reaction. AIDS 2002;16:1696-7. DOI 10.1097/00002030-200208160-00022
14. Sankatsing SUC, Prins JM. Agranulocytosis and fever seven weeks after starting abacavir. AIDS 2001;15:2464-5. DOI 10.1097/00002030-200112070-00021
15. Tikhomirov V, Namek K, Hindes R. Agranulocytosis induced by abacavir (letter). AIDS 1999;13:1420. DOI 10.1097/00002030-199907300-00027
16. Herring SJ, Krieger AC. Acute respiratory manifestations of the abacavir hypersensitivity reaction. AIDS 2006;20:301-2. DOI 10.1097/01.aids.0000199833. 87606.95
17. Del Giudice P, Vandenbos F, Perrin C, Bernard E, Marq L, Dellamonica P. Sweet's syndrome following abacavir therapy. J Am Acad Dermatol 2004;51:474-5.
18. Bossi P, Roujeau JC, Bricaire F, Caumes E. Stevens-Johnson syndrome associated with abacavir therapy (letter). Clin Infect Dis 2002;35:902. DOI 10.1086/342571
19. Walensky RP, Goldberg JH, Daily JP. Anaphylaxis after rechallenge with abacavir. AIDS 1999;13:999-1000. DOI 10.1097/00002030-199905280-00022
20. Escaut L, Liotier JY, Albengres E, Cheminot N, Vittecoq D. Abacavir rechallenge has to be avoided in case of hypersensitivity reaction. AIDS 1999;13:1419-20. DOI 10.1097/00002030-199907300-00026
21. Shapiro M, Ward KM, Stern JJ. A near-fatal hypersensitivity reaction to abacavir: case report and literature review. AIDS Read 2001;11:222-6.
22. Frissen PH, de Vries J, Weigel HM, Brinkman K. Severe anaphylactic shock after rechallenge with abacavir without preceding hypersensitivity. AIDS 2001;15:289. DOI 10.1097/00002030-200101260-00027
23. Aquilina C, Mjularczyk M, Lucas F, Viraben R. Unusual clinical presentation of hypersensitivity reaction to abacavir. AIDS 2003;17:2403-4. DOI 10.1097/00002030-200311070-00021
24. Loeliger AE, Steel H, McGuirk S, Powell WS, Hetherington SV. The abacavir hypersensitivity reaction and interruptions in therapy. AIDS 2001;15:1325-6. DOI 10.1097/00002030-200107060-00022
25. Sahly HM. Development of abacavir hypersensitivity reaction after rechallenge in a previously asymptomatic patient. AIDS 2004;18:359-60. DOI 10.1097/00002030-200401230-00041
26. Gervasoni C, Vigano O, Grinelli E, Ortu M, Galli M, Rusconi S. Abacavir hypersensitivity reaction after switching from the twice-daily to the once-daily formulation. AIDS Patient Care STDS. 2007;21:1-3. DOI 10.1089/apc.2006.0056
27. Berenguer J, Padilla B, Estrada V, et al. Safety of abacavir therapy after temporary interruptions in patients without hypersensitivity reactions to the drug. AIDS 2002;16:1299-301. DOI 10.1097/00002030-200206140-00018
28. Symonds W, Cutrell A, Edwards M, et al. Risk factor analysis of hypersensitivity reactions to abacavir. Clin Ther 2002;24:565-73. DOI 10.1016/S0149-2918(02)85132-3
29. Easterbrook PJ, Waters A, Murad S, et al. Epidemiological risk factors for hypersensitivity reactions to abacavir. HIV Med 2003;4:321-4. DOI 10.1046/j.1468-1293.2003.00166.x
30. Hernandez J, Williams V, Shaefer M, et al. The rate of hypersensitivity reactions to abacavir is similar in underrepresented populations and incarcerated subjects (GW protocols NZTA4002, 4005, 4006, 4007). AIDS 2000;14(suppl 4):S69. DOI 10.1097/00002030-200001070-00008
31. Cutrell AG, Hernandez JE, Fleming JW, et al. Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir (letter). Ann Pharmacother 2004;38:2171-2. Epub 9 Nov 2004. DOI 10.1345/aph.1E202
32. Hernandez J, Cutrell A, Bonny T, et al. Diagnosis of abacavir hypersensitivity reactions among patients not receiving abacavir in two blinded studies (abstract 134). Antivir Ther 2003;8:L88.
33. Goedken AM, Herman RA. Once-daily abacavir in place of twice-daily administration. Ann Pharmacother 2005;39:1302-8. Epub 14 Jun 2005. DOI 10.1345/aph.1E680
34. James A, Johann-Liang R. Increased rate and severity of abacavir-associated hypersensitivity reaction in randomised controlled clinical trials (abstract 835). Presented at: 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 22-25, 2005.
35. Moyle GJ, DeJesus E, Cahn P, et al. Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen once daily in antiretroviral combination study. J Acquir Immune Defic Syndr 2005;38:417-25. DOI 10.1097/01.qai.0000147521.34369.c9
36. Stekler J, Maenza J, Stevens C, et al. Abacavir hypersensitivity reaction in primary HIV infection. AIDS 2006;20:1269-74. DOI 10.1097/01.aids.0000232234. 19006.a2
37. Peyrieere H, Nicolas J, Siffert M, Demoly P, Hillaire-Buys D, Reynes J. Hypersensitivity related to abacavir in two members of a family (letter). Ann Pharmacother 2001;35:1291-2. DOI 10.1345/aph.1A022
38. Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002;359:1121-2. DOI 10.1016/S0140-6736(02)08158-8
39. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002;359:727-32. DOI 10.1016/S0140-6736(02)07873-X
40. Martin AM, Nolan D, Gaudieri S, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-hom variant. Proc Natl Acad Sci U S A 2004;101:4180-5. DOI 10.1073/pnas.0307067101
41. Hughes AR, Mosteller M, Bansal AT, et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 2004;5:203-11.
42. Hetherington S. Understanding drug hypersensitivity: what to look for when prescribing abacavir. AIDS Read 2001;11:620-2.
43. Keiser P, Nassar N, Skiest D, et al. Comparison of symptoms of influenza A with abacavir-associated hypersensitivity reaction. Int J STD AIDS 2003;14:478-81. DOI 10.1258/095646203322025795
44. Phillips EJ, Sullivan JR, Knowles SR, Shear NH. Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. AIDS 2002;16:2223-5. DOI 10.1097/00002030-200211080-00017
45. Phillips EJ, Wong GA, Kaul R, et al. Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS 2005;19:979-81. DOI 10.1097/01.aids.0000171414.99409.fb
46. Wit FW, Wood R, Horban A, et al. Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine. AIDS 2001;15:2423-9. DOI 10.1097/00002030-200112070- 00010
47. Nolan D, Gaudieri S, Mallal S. Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity? J HIV Ther 2003;8:36-41.
48. Phillips EJ. Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet? Clin Infect Dis 2006;43:103-5. DOI 10.1086/504878
49. Rauch A, Nolan D, Martin A, McKinnon E, Almeida C, Mallal S. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis 2006;43:99-102. DOI 10.1086/504874
50. Zucman D, Truchis P, Majerholc C, Stegman S, Caillat-Zucman S. Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. J Acquir Immune Defic Syndr 2007;45:1-3. DOI 10.1097/QAI.0b013e318046ea31
51. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008;358:568-79.
52. Machouf N, Trottier B, Thomas R, Nguyen VK. Patients seem more secure when they initiate abacavir after an HLA-B*5701 screening (abstract). Can J Infect Dis Med Microbiol 2007;18(suppl B):64B.
53. Reeves I, Churchill D, Fisher M. Screening for HLA- B*5701 reduces the frequency of abacavir hypersensitivity reactions (abstract 14). Antivir Ther 2006;11:L11.
54. Saag M, Balu R, Brachman P, et al. High sensitivity of HLA-B*5701 in whites and blacks in immunologically-confirmed cases of abacavir hypersensitivity (ABC HSR) (abstract WEAB305). Presented at: 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, Australia, July 22-25, 2007.
55. Hughes DA, Vilar FJ, Ward CC, Alfirevic A, Park BK, Pirmohamed M. Cost-effectiveness analysis of HLA-B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 2004;14:335-42. DOI 10.1097/00008571-200406000-00002
56. Veenstra DL. Bringing genomics to the bedside: a cost-effective pharmacogenomic test? Pharmacogenetics 2004;14:333-4.